Synthesis of site-specific antibody-drug conjugates using unnatural amino acids - Test2 - elhamkhani - TriplyDB

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

http://www.wikidata.org/entity/Q24624489

about

Non-standard amino acid incorporation into proteins using Escherichia coli cell-free protein synthesis Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs)Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics Antibody-drug conjugates as novel anti-cancer chemotherapeutics Site-specific functionalization of proteins and their applications to therapeutic antibodies An overview of clinical and commercial impact of drug delivery systems Multivalent polymers for drug delivery and imaging: the challenges of conjugation Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy Site-Specifically Labeled Immunoconjugates for Molecular Imaging--Part 1: Cysteine Residues and Glycans In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry In-frame amber stop codon replacement mutagenesis for the directed evolution of proteins containing non-canonical amino acids: identification of residues open to bio-orthogonal modification Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer Advances in Antibody Design Current Status: Site-Specific Antibody Drug Conjugates Adapter reagents for protein site specific dye labeling Effects of Non-Natural Amino Acid Incorporation into the Enzyme Core Region on Enzyme Structure and Function.Bioconjugation of therapeutic proteins and enzymes using the expanded set of genetically encoded amino acids.Genetic Incorporation of the Unnatural Amino Acid p-Acetyl Phenylalanine into Proteins for Site-Directed Spin Labeling At the Interface of Chemical and Biological Synthesis: An Expanded Genetic Code.Translation system engineering in Escherichia coli enhances non-canonical amino acid incorporation into proteins.Enabling the controlled assembly of antibody conjugates with a loading of two modules without antibody engineering Chemoenzymatic site-specific reversible immobilization and labeling of proteins from crude cellular extract without prior purification using oxime and hydrazine ligation RF1 attenuation enables efficient non-natural amino acid incorporation for production of homogeneous antibody drug conjugates.Cell-free protein synthesis from a release factor 1 deficient Escherichia coli activates efficient and multiple site-specific nonstandard amino acid incorporation.Cancer targeted therapeutics: From molecules to drug delivery vehicles.Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions.Versatile strategy for controlling the specificity and activity of engineered T cells.Site-specific protein transamination using N-methylpyridinium-4-carboxaldehyde.Facile method for the site-specific, covalent attachment of full-length IgG onto nanoparticles In vitro and in vivo application of anti-cotinine antibody and cotinine-conjugated compounds.Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes Mistranslation of the genetic code.Development of a recombinant antibody to target peptides and proteins to sialoadhesin-expressing macrophages.Protein conjugation with genetically encoded unnatural amino acids.Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development Methods to Make Homogenous Antibody Drug Conjugates.Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar Improving cell-free protein synthesis through genome engineering of Escherichia coli lacking release factor 1 Optimisation of a system for the co-translational incorporation of a keto amino acid and its application to a tumour-specific Anticalin.

P2860

Q21131315-B1D45606-FC97-43F9-AA2B-407B50A435E2 Q26768654-D9D05A50-C7DF-4477-96A2-588F256A965B Q26780335-37311FEE-13C7-480F-BF0E-43427B14630A Q26800175-72ADCF27-A7D6-410A-B217-3B28F4BE5E1B Q26830699-610FA764-4739-433F-9D2A-9449FB6F4CA5 Q27007143-A2DA77C1-AF6A-4CFC-BC2D-5DD5CB46C19C Q27692689-0F554D93-887E-48E7-851E-ECA3E0D6E632 Q27701980-07FC7110-7183-4F69-B8ED-347AEDC5F1A6 Q28078378-5DE51185-AC7E-4FCE-BADF-6D48772A1264 Q28538658-AE06A554-D97D-44AE-82A6-F48E86D817D2 Q28544658-79AFDBFE-0E2B-4ED3-B970-367C2B9A4468 Q28547469-B3CD08D9-605C-426C-9464-2F39DA929A21 Q28552050-630C1282-5431-47F5-A7D9-3A897FADC8DD Q28817608-46383136-47C9-49E0-8B12-5062F194C727 Q28829290-1B36229C-EEBC-4255-A29C-D363209EB783 Q28833748-27DF0662-8712-48EF-AF69-71FFD5D2D328 Q30278633-30C2AAAC-B699-4A53-96E8-7C12CAD0A757 Q30279245-4BC12B91-A316-4953-915C-B9F3CBDB67FD Q30380436-09F469FC-4BD6-4716-BF9B-3A2884E73E10 Q30390524-C94059AE-CA79-47E2-8907-FBDB452A4DAC Q30396587-C06D4D1D-9112-425A-BCBE-C29D29693CC4 Q33587970-FEECBFB4-07EA-45C1-991D-000E70583E13 Q33679349-0ADF41CD-8C55-4FAB-9C16-C2BFCE4EC817 Q33780009-7E557EE6-C15C-4C10-A76A-ABA5B99C3B97 Q33786525-874E9E57-EE3C-4607-8586-CD49CB2EB107 Q33887986-7FB5A023-FB7E-4EB3-81F3-7B8D4F8D43FC Q34026374-B2835126-F197-468D-BFA0-8DB23830D7CE Q34045831-C60B129A-AF07-462C-86C3-0E2B2FA507BB Q34059746-64C3F47E-7E44-4AA5-9D73-A497B7C5F34F Q34079536-8B7AFA7A-0505-4B54-95C0-E1D6C53BB404 Q34180012-09707D14-8A4E-47D4-AF8D-DF16554D2214 Q34434128-E72F5923-CF3F-4976-A150-157850EBA7F7 Q34438631-41EBACC9-13CD-47C4-8611-BC45F5203BF3 Q34663064-87BE3C17-AACF-43C8-94DA-77550176B7DD Q34838057-9B247C27-33CC-4525-B35D-0CFAE0580DC3 Q35105725-39754565-F15B-4DCF-9623-C336C451DBCF Q35523479-7E2E774E-BB76-4CD1-BD2C-8905CB0DAA9D Q35526950-AD66571A-30B2-48C4-A368-E06FFEB7CED2 Q35566287-B756F92B-8150-4F16-AF90-B5F22855BD48 Q35787407-C0F4FE9F-207E-4EF5-AC4D-2D4A0A267EB4

P2860

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

http://www.wikidata.org/entity/Q24624489

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

@ast

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

@en

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

@nl

type

label

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

@ast

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

@en

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

@nl

prefLabel

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

@ast

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

@en

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

@nl

P1433

Q24624489-3BE6D7B7-C1C3-41E7-A90F-8041224179F2

P1476

Q24624489-AEAB0190-8049-400E-97F6-5CE56FC5AD12

P2093

Q24624489-06AF5745-4FBE-4D18-8F17-08D62AA8E523

Q24624489-09246C70-B529-4D39-B93C-AF8F2B907650

Q24624489-12FE9DD3-E239-42EE-81E9-2B24B4362C0D

Q24624489-149E4C95-122E-4FD6-84C4-74B51F1CDA2E

Q24624489-1876CA73-885C-4461-A1B7-C96EB2EBF837

Q24624489-2DDC1930-FB87-434B-AB84-8002922141B8

Q24624489-38554E59-96EF-484A-8529-2371B0B2D2E5

Q24624489-4615903D-51CF-413E-95E3-BA5E01C233D4

Q24624489-56EFE091-F6C8-419F-A955-00C34E6B90A7

Q24624489-6F873F3F-65C0-46AF-B0E5-A06AD546E1B1

P2860

Q24624489-0A719431-7B12-4D36-B239-07D849D1EF49

Q24624489-197E1D7E-D07D-4AEF-929F-DC3F8F81A9F3

Q24624489-279BAA63-0CD9-49E5-AFEE-19EC29542C0F

Q24624489-392C30CD-626B-42B0-8151-CDE299DAA0B7

Q24624489-3D492AF3-282A-4B9D-A9C5-EE202FF3955B

Q24624489-40A6F8C9-DF78-4A31-ACF5-08EA21303E02

Q24624489-4462CC1A-1AD1-4C56-84DD-ADC94DCD788C

Q24624489-455C211A-1660-466C-BC4A-68B5F9A9FD1F

Q24624489-493C6D98-3723-4B70-B166-F3E1C1F3ADC7

Q24624489-52A6A157-E3CB-4A35-B748-463DD90EC0BF

P304

Q24624489-2ABD8FA8-CC9B-43F3-BA70-43AF88463BE2

P31

Q24624489-13E93CA1-A3F6-46FC-8E7B-B0CFC5802B6A

P3181

Q24624489-BEB34F92-55DA-4074-8EE8-8331D4DE1437

P356

Q24624489-802BB33A-F6E6-415A-A5F7-BDD208FBC2B5

P407

Q24624489-8D3A6F8E-7A6E-4501-AB4A-B399A6316F28

P433

Q24624489-5DBDCE7C-B67B-4AE9-AAE4-9D274E0DF0D7

P478

Q24624489-18FAECA2-28CB-4D7A-92B2-CB1AAD256B2F

P577

Q24624489-0088D6B9-7F8B-4A8A-BF6B-7F241BE8B73C

P5875

Q24624489-AA644A20-EAA2-4A05-9360-EFF6C54668E3

P698

Q24624489-25CD9D58-870F-4FE8-B846-76EBBFFDAF29

P921

Q24624489-CED81C98-F1A1-46DA-BC05-C475822E8592

P932

Q24624489-DDBBEDFC-F8A9-4E98-B3B3-784439E138D7

P3181

P356

PNAS.1211023109

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

@en

P2093

Aaron J Seller

http://www.w3.org/2001/XMLSchema#string

Aga Szydlik

http://www.w3.org/2001/XMLSchema#string

Antonio F Santidrian

http://www.w3.org/2001/XMLSchema#string

Benjamin M Hutchins

http://www.w3.org/2001/XMLSchema#string

Brunhilde Felding-Habermann

http://www.w3.org/2001/XMLSchema#string

Chan Hyuk Kim

http://www.w3.org/2001/XMLSchema#string

Feng Tian

http://www.w3.org/2001/XMLSchema#string

Hon Tran

http://www.w3.org/2001/XMLSchema#string

Jane S Forsyth

http://www.w3.org/2001/XMLSchema#string

Jason K Pinkstaff

http://www.w3.org/2001/XMLSchema#string

P2860

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

Expanding the genetic code of Escherichia coli

Nucleophilic catalysis of oxime ligation

CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

Addition of the keto functional group to the genetic code of Escherichia coli.

Synthesis of LJP 993, a multivalent conjugate of the N-terminal domain of beta2GPI and suppression of an anti-beta2GPI immune response.

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

P304

16101-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

542687

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.1211023109

http://www.w3.org/2001/XMLSchema#string

P407

P433

40

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230871872

http://www.w3.org/2001/XMLSchema#string

P698

22988081

http://www.w3.org/2001/XMLSchema#string

P921

P932

3479532

http://www.w3.org/2001/XMLSchema#string